title: Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?
authors.affiliation: Neuro-Urology, Swiss Paraplegic Center, Balgrist University Hospital, Zurich, Switzerland. areitz@balgrist.unizh.ch
authors.forename: André
authors.initials: A
authors.lastname: Reitz
authors.forename: Michael
authors.initials: M
authors.lastname: Müntener
authors.forename: Axel
authors.initials: A
authors.lastname: Haferkamp
authors.forename: Markus
authors.initials: M
authors.lastname: Hohenfellner
authors.forename: Brigitte
authors.initials: B
authors.lastname: Schurch
mesh_terms: D006152:Cyclic GMP / Q000378:metabolism*; D006801:Humans; D008297:Male; D009126:Muscle Relaxation / Q000502:physiology; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000378:metabolism; D001748:Urinary Bladder Neck Obstruction / Q000378:metabolism / Q000517:prevention & control*
chemical_list: D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D009569:Nitric Oxide; D006152:Cyclic GMP